SEC filer · CIK 0000883975 · MBOT
Microbot Medical Inc.
Microbot Medical net income: -$13.1 million for the year ending 2025-12-31. Total assets: $81.5 million at 2025-12-31.
Every reported measure
The latest value of each measure the company reports, as filed. Choose one for its full history, its definition and the filing behind each figure. Separate currencies and reporting intervals stay separate rows; these are reported amounts, not prices.
| Measure | Period start | Period end | Value | Filed |
|---|---|---|---|---|
| Total assets | - | 2025-12-31 | $81.5 million | 2026-03-26 |
| Total liabilities | - | 2025-12-31 | $3.99 million | 2026-03-26 |
| Stockholders equity | - | 2025-12-31 | $77.6 million | 2026-03-26 |
| Cash and cash equivalents | - | 2025-12-31 | $3.91 million | 2026-03-26 |
| Net income or loss | 2025-01-01 | 2025-12-31 | -$13.1 million | 2026-03-26 |
| Operating cash flow | 2025-01-01 | 2025-12-31 | -$13.0 million | 2026-03-26 |
| Capital expenditure payments | 2025-01-01 | 2025-12-31 | $60.0 thousand | 2026-03-26 |
| Financing cash flow | 2025-01-01 | 2025-12-31 | $86.2 million | 2026-03-26 |
| Investing cash flow | 2025-01-01 | 2025-12-31 | -$72.4 million | 2026-03-26 |
| Retained earnings or deficit | - | 2025-12-31 | -$104.1 million | 2026-03-26 |
| Basic weighted-average shares | 2025-01-01 | 2025-12-31 | 45.8 million shares | 2026-03-26 |
| Diluted weighted-average shares | 2025-01-01 | 2025-12-31 | 45.8 million shares | 2026-03-26 |
| Basic earnings per share | 2025-01-01 | 2025-12-31 | -$0.29 per share | 2026-03-26 |
| Diluted earnings per share | 2025-01-01 | 2025-12-31 | -$0.29 per share | 2026-03-26 |
| Net property, plant and equipment | - | 2025-12-31 | $93.0 thousand | 2026-03-26 |
| Share-based compensation expense | 2025-01-01 | 2025-12-31 | $1.06 million | 2026-03-26 |
| Operating income or loss | 2025-01-01 | 2025-12-31 | -$14.7 million | 2026-03-26 |
| Current assets | - | 2025-12-31 | $79.8 million | 2026-03-26 |
| Current liabilities | - | 2025-12-31 | $3.42 million | 2026-03-26 |
| Current accounts payable | - | 2025-12-31 | $511.0 thousand | 2026-03-26 |
| Selling, general and administrative expense | 2025-01-01 | 2025-12-31 | $8.46 million | 2026-03-26 |
| Research and development expense | 2025-01-01 | 2025-12-31 | $6.28 million | 2026-03-26 |
| Common shares outstanding | - | 2025-12-31 | 67.2 million shares | 2026-03-26 |
| Operating lease right-of-use asset | - | 2025-12-31 | $833.0 thousand | 2026-03-26 |
| Operating lease liability | - | 2025-12-31 | $865.0 thousand | 2026-03-26 |
| Gross property, plant and equipment | - | 2025-12-31 | $724.0 thousand | 2026-03-26 |
| Accumulated depreciation on property, plant and equipment | - | 2025-12-31 | $631.0 thousand | 2026-03-26 |
| Accrued current liabilities | - | 2025-12-31 | $2.61 million | 2026-03-26 |
| Prepaid expenses and other current assets | - | 2025-12-31 | $644.0 thousand | 2026-03-26 |
| Net deferred tax assets | - | 2025-12-31 | $191.0 thousand | 2026-03-26 |
| General and administrative expense | 2024-01-01 | 2024-12-31 | $5.00 million | 2025-03-25 |
| Depreciation, depletion and amortization | 2025-01-01 | 2025-12-31 | $47.0 thousand | 2026-03-26 |
| Interest paid, net | 2024-01-01 | 2024-12-31 | $171.0 thousand | 2025-03-25 |
| Operating lease payments | 2025-01-01 | 2025-12-31 | $212.0 thousand | 2026-03-26 |
Older measures: 20 not reported in the two years before 2026-09-20
| Measure | Period start | Period end | Value | Filed |
|---|---|---|---|---|
| Revenue | 2015-01-01 | 2015-12-31 | $116.9 thousand | 2016-03-15 |
| Interest expense | 2017-01-01 | 2017-12-31 | $237.0 thousand | 2019-04-01 |
| Goodwill carrying amount | - | 2013-12-31 | $2.14 million | 2015-03-13 |
| Net current accounts receivable | - | 2014-12-31 | $159.5 thousand | 2016-03-15 |
| Operating expenses | 2015-01-01 | 2015-12-31 | $36.8 million | 2016-03-15 |
| Gross profit | 2013-01-01 | 2013-12-31 | $886.6 thousand | 2014-03-13 |
| Cash including restricted cash | - | 2018-12-31 | $5.26 million | 2019-04-01 |
| Additional paid-in capital | - | 2018-12-31 | $32.5 million | 2019-04-01 |
| Accumulated other comprehensive income or loss | - | 2015-12-31 | $47.4 thousand | 2016-03-15 |
| Net intangible assets excluding goodwill | - | 2015-12-31 | $45.8 thousand | 2016-03-15 |
| Other noncurrent assets | - | 2015-12-31 | $742.7 thousand | 2016-03-15 |
| Profit or loss including noncontrolling interests | 2019-01-01 | 2019-12-31 | $7.25 million | 2020-04-14 |
| Comprehensive income or loss | 2020-01-01 | 2020-12-31 | -$9.17 million | 2021-03-31 |
| Net income available to common stockholders | 2019-01-01 | 2019-12-31 | $7.25 million | 2020-04-14 |
| Depreciation expense | 2018-01-01 | 2018-12-31 | $54.0 thousand | 2019-04-01 |
| Amortization of intangible assets | 2015-01-01 | 2015-12-31 | $72.0 thousand | 2016-03-15 |
| Other nonoperating income or expense | 2022-01-01 | 2022-12-31 | -$5000 | 2023-03-31 |
| Nonoperating income or expense | 2015-01-01 | 2015-12-31 | $305.4 thousand | 2016-03-15 |
| Proceeds from issuing common stock | 2019-01-01 | 2019-12-31 | $36.8 million | 2021-03-31 |
| Change in accounts receivable | 2015-01-01 | 2015-12-31 | -$155.4 thousand | 2016-03-15 |
Filings
- 10-Q filed 2026-08-11
- 10-Q filed 2026-05-13
- 10-K filed 2026-03-26
- 10-Q filed 2025-11-12
- 10-Q filed 2025-08-12
61 Microbot Medical filings with published measures: what each annual or quarterly report tagged, with the periods it covered, as reported in that filing. The histories above show the latest-filed value per period.
Inspect the source
- Entity
- MICROBOT MEDICAL INC. / CIK 0000883975
- Captured
- SEC response SHA-256
5fc792c757c83821aa0cd636b3655419924829213ef914d8be1d9f56dce19054
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000883975.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))